# Network pharmacology of cellular targets in major depressive disorder and differential mechanisms of fluoxetine, ketamine and esketamine

## TL;DR

This study uses network pharmacology to explore how antidepressants like fluoxetine, ketamine, and esketamine work in major depressive disorder and identifies key molecular targets for improved treatment.

## Contribution

The paper introduces a network pharmacology approach to uncover shared and distinct mechanisms of antidepressants and identifies novel therapeutic targets in MDD.

## Key findings

- GSK3B, OPRM1, and EGFR are key druggable targets in MDD.
- NFKB is a central regulator linking inflammation, synaptic plasticity, and metabolism in MDD.
- Targeted modulation of these genes may improve antidepressant efficacy and treatment strategies.

## Abstract

Major depressive disorder (MDD) is a multifactorial mental health condition involving genetic, environmental, and neurobiological factors. Conventional antidepressants such as fluoxetine, a selective serotonin reuptake inhibitor, require weeks to exert therapeutic effects, whereas ketamine and esketamine act rapidly via glutamatergic modulation. These drugs may also converge on the inhibition of glycogen synthase kinase 3 beta (GSK3B) as a key mechanism for their antidepressant effects, increasing neuroplasticity, synaptic transmission, and neuronal survival through upregulation of brain-derived neurotrophic factor (BDNF). Part of the antidepressant effects of ketamine also seems to depend on opioid receptor activation. Despite recent progress, variability in antidepressant response in MDD remains unclear. This work explores, via meta-analysis and network fragility analysis, key molecular mechanisms in MDD, how these drugs exert actions, and highlights potential therapeutic targets for MDD. We performed a network pharmacology approach to unravel the key cellular processes involved in MDD, including altered synaptic plasticity, neurogenesis, apoptosis, and neuroinflammation. Second, we explored the therapeutic role of these treatments on these altered cellular processes. By integrating drug-target data with MDD-associated genes, we identified the opioid receptor mu 1 (OPRM1), epidermal growth factor receptor (EGFR) and GSK3B as key druggable targets. Network analysis further suggested that nuclear factor kappa B (NFKB) may regulate all three, positioning it as a central node linking inflammation, synaptic plasticity, and neuronal metabolism in MDD. We hypothesize that targeted modulation of these genes may optimize the therapeutic efficacy, while NFKB emerges as a promising candidate biomarker for guiding treatment strategies in MDD.